Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cidara Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CDTX
Nasdaq
8731
https://www.cidara.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cidara Therapeutics Inc
Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024
- Apr 5th, 2024 7:00 pm
Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association for Cancer Research (AACR) Annual Meeting 2024
- Mar 6th, 2024 1:00 pm
Steven Cohen's Point72 Adds Cidara Therapeutics to Its Portfolio
- Feb 15th, 2024 8:15 am
Cidara Therapeutics Receives $11.14 Million Milestone Payment Following European Approval of REZZAYO
- Feb 12th, 2024 1:00 pm
Cidara Therapeutics Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults
- Jan 29th, 2024 9:30 pm
Cidara (CDTX) Up on EC Nod for Rezzayo in Invasive Candidiasis
- Dec 26th, 2023 3:51 pm
Cidara Therapeutics Announces European Approval of REZZAYO® (rezafungin) for the Treatment of Invasive Candidiasis in Adults
- Dec 22nd, 2023 12:30 pm
Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
- Dec 7th, 2023 1:00 pm
Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China
- Dec 6th, 2023 1:00 pm
Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress
- Nov 30th, 2023 1:00 pm
Cidara Therapeutics Named as a San Diego Metro Area Top Workplace
- Nov 20th, 2023 1:00 pm
Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting
- Nov 3rd, 2023 4:00 pm
Cidara Therapeutics Inc (CDTX) Reports Q3 2023 Financial Results
- Nov 2nd, 2023 11:33 pm
Cidara Therapeutics Provides Corporate Update and Reports Third Quarter 2023 Financial Results
- Nov 2nd, 2023 8:15 pm
Cidara Therapeutics (NASDAQ:CDTX) Is In A Strong Position To Grow Its Business
- Oct 21st, 2023 1:37 pm
Cidara Therapeutics and Mundipharma receive positive CHMP opinion for rezafungin for the treatment of Invasive Candidiasis in adults(1)
- Oct 13th, 2023 2:34 pm
Cidara Therapeutics Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023
- Oct 11th, 2023 12:30 pm
Cidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Sep 29th, 2023 8:51 pm
Cidara Therapeutics to Present New Data on Novel drug-Fc conjugate CD388 at IDWeek 2023
- Sep 27th, 2023 12:00 pm
Insider Sell: Chief Scientific Officer Leslie Tari Sells 18,469 Shares of Cidara Therapeutics Inc
- Sep 14th, 2023 5:17 am
Scroll